Progressive and de novo MIBC groups present different prognostic biomarkers for tumor progression (RBPMS2 in progressive MIBC and DSC3 in de novo MIBC) and for CSS (CALD1 in progressive MIBC and LCOR in de novo MIBC). Here, RBPMS2 is linked to neoplasm.